logo image

Glibenclamide + Metformin information from DrugsUpdate  

See Available Brands of Glibenclamide + Metformin in India

P - Contraindicated in pregnancy
L - Contraindicated in lactation

Information Not Available



Glibenclamide stimulates insulin secretion from pancreatic β-cells, reduces hepatic gluconeogenesis and lowers blood-glucose concentrations. Metformin improves glucose tolerance in patients with type 2 DM, lowering both basal and postprandial blood glucose. It decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilisation.

Glibenclamide: Extensively bound to serum proteins. Metformin: Negligible binding to serum proteins.

Glibenclamide: Terminal half-life: About 10 hours; excreted in urine and bile (approx 50% by each route).

Glibenclamide + Metformin Indications / Glibenclamide + Metformin Uses

Information Not Available

Glibenclamide + Metformin Adverse Reactions / Glibenclamide + Metformin Side Effects

Hypoglycaemia; cholestatic jaundice; agranulocytosis; aplastic anaemia; haemolytic anaemia. Blood dyscrasias (reversible), liver dysfunction, hypoglycaemia, GI symptoms, allergic skin reactions. Metformin: Lactic acidosis with alcohol and potentiation of hypoglycaemic effect. Cimetidine and furosemide may increase plasma-metformin levels. Drugs eliminated via renal tubular secretion may increase metformin levels.

Potentially Fatal: Glibenclamide: Prolonged hypoglycaemia seen in elderly or debilitated patients with hepatic or renal diseases. Metformin: Lactic acidosis in presence of renal failure and alcoholism.


Information Not Available

Special Precautions

Overdosage; elderly; dietary errors; mild to moderate renal and hepatic disorders. Impaired alertness. Avoid alcohol. Carefully monitor blood-glucose concentration.

Other Drug Interactions

Glibenclamide: Adrenaline, aminoglutethimide, chlorpromazine, corticosteroids, diazoxide, OC and thiazide diuretics diminish hypoglycaemic effect of glibenclamide. ACE inhibitors, alcohol, some analgesics, azole antifungals, coumarin, MAOIs, octreotide, tetracyclines, tricyclic antidepressants increase hypoglycaemic effects of glibenclamide. Metformin: Additive effect with sulphonylureas. Antagonistic effects with diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers and isoniazid.

Potentially Fatal: Glibenclamide: Warfarin, salicylates, sulphonamides and alcohol potentiate hypoglycaemic effect. Glucocorticoids, diuretics and oestrogen reduce hypoglycaemic effect. Beta-blockers mask early symptoms of hypoglycaemia.

Other Interactions

Information Not Available


Type 2 diabetes mellitus
Adult: Per tablet contains glibenclamide 1.25 mg and metformin 250 mg. As initial therapy: Start with 1 tablet once or twice daily. May increase in steps of 1 tablet/day every 2 weeks to the lowest effective dose need to achieve effective control of blood glucose. For patients previously treated with glibenclamide/sulphonylurea or metformin alone: Initiate with 2-4 tablets daily in divided doses; starting doses should not exceed the daily doses of glibenclamide or metformin already being taken; max: 8 tablets/day.


Information Not Available

List of Contraindications

Glibenclamide + Metformin and Pregnancy

Contraindicated in pregnancy

Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).

Glibenclamide + Metformin and Lactation

Contraindicated in lactation

Glibenclamide + Metformin and Children

Information Not Available

Glibenclamide + Metformin and Geriatic

Information Not Available

Glibenclamide + Metformin and Other Contraindications

Severe or life-threatening hyperglycaemia; liver disease; severe renal failure; juvenile diabetes, ketoacidosis, pre-coma and diabetic coma; adrenocortical insufficiency. Pregnancy and lactation. Hypersensitivity, cardiac failure, recent MI, CHF. IDDM; severe infection; acute or chronic metabolic acidosis with or without coma; stress, trauma; severe impairment of thyroid function; dehydration, acute or chronic alcoholism.


Information Not Available

Lab interference

Information Not Available

© 2011-2020 DrugsUpdate.com. Disclaimer | Site Map

  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.